Webcast ImageWebcast
CTI BioPharma Corp at Ladenburg Thalmann 2015 Healthcare Conference (Replay)
09/29/15 at 11:00 a.m. ET

CTI BioPharma is a biopharmaceutical company whose mission is to acquire, develop and bring to market less toxic, more effective ways to treat and cure cancer. Our therapeutic focus is on novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. We have a commercial product, PIXUVRI®, available in certain markets in Europe, as well as a diverse late-stage development pipeline that we believe will drive future growth of our company. We are headquartered in Seattle, Washington, with offices in London and Milan. Our management and investor relations team provide updates throughout the year through conference calls, investor events, press releases and SEC filings. We invite you to sign up for our investor alerts and listen to our archived and live presentations.

To CTI’s knowledge, all press releases, scientific papers and abstracts, and the information contained within them were timely and accurate when issued. The continued accuracy of this material beyond the date of issuance and posting on the website is not assured. CTI has no intention of updating this information and specifically disclaims any duty to do so. These documents may contain forward-looking statements. Actual results could vary dramatically as a result of known and unknown risks and uncertainties. Please see Terms of Use for this website.

IR Contacts

  • Current Quote
  • Stock Chart
$1.59 + 0.08 (0.00%)
Day High:$1.60
Day Low:$1.51
10/05/154:00 p.m. ET
Delayed at least 15 minutes.

Monique Greer
T +1 206-272-4343
Ed Bell
T +1 206-272-4345

CTI Life Sciences Limited, Milan Branch

Recent News

Oct 01, 2015CTI BioPharma And Fred Hutchinson Cancer Research Center Announce International Research Fellowship To Support Innovative Blood-Related Cancer Research
SEATTLE, Oct. 1, 2015 /PRNewswire/ -- Seattle-based CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) and Fred Hutchinson Cancer Research Center (Fred Hutch) today announced the establishment of a new $1.5 million research endowment fund – The CTI BioPharma International Postdoctoral Research Fellowship – intended to foster international collaboration in translational research and support advancements in the fields of hematology and immunobiology.     "Establishing this endowed inter... 
Printer Friendly Version
Sep 24, 2015CTI BioPharma Announces $15.7 Million Registered Direct Offering
SEATTLE, Sept. 24, 2015 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA: CTIC) today announced that it has entered into an agreement with institutional investors to purchase 10 million shares of the Company's common stock in a registered direct offering conducted without an underwriter or placement agent for gross proceeds to the Company of approximately $15.7 million at a purchase price per share of $1.57 (the "Offering"), equal to the consolidated closing bid price on The NASDAQ Global Mar... 
Printer Friendly Version
Sep 24, 2015CTI BioPharma to Present at the Ladenburg Thalmann 2015 Healthcare Conference
SEATTLE, Sept. 24, 2015 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA: CTIC) announced today that management will present at the Ladenburg Thalmann 2015 Healthcare Conference on Tuesday, September 29 at 8:00 a.m. PDT/11:00 a.m. EDT/5:00 p.m. CEST in New York. The presentation will also be webcast live and available for replay after the presentation. The webcast can be accessed at About CTI BioPharma CTI BioPharma Corp. (NASDAQ and MTA: CTIC) is a biopharmac... 
Printer Friendly Version


Sep 29, 2015
CTI BioPharma Corp at Ladenburg Thalmann 2015 Healthcare Conference
Aug 06, 2015
Q2 2015 CTI BioPharma Corp Earnings Conference Call
Data provided by Nasdaq. Minimum 15 minutes delayed.